Background-In contrast to clear associations between variants in genes participating in low-density lipoprotein metabolism and cardiovascular disease risk, such associations for high-density lipoprotein (HDL)-related genes are not well supported by recent large studies. We aimed to determine whether genetic variants at the locus encoding phospholipid transfer protein (PLTP), a protein involved in HDL remodeling, underlie altered PLTP activity, HDL particle concentration and size, and cardiovascular disease risk. Methods and Results-We assessed associations between 6 PLTP tagging single nucleotide polymorphisms and PLTP activity in 2 studies (combined nϭ384) and identified 2 variants that show reproducible associations with altered plasma PLTP activity. A gene score based on these variants is associated with lower hepatic PLTP transcription (Pϭ3.2ϫ10 Ϫ18 ) in a third study (nϭ957) and with an increased number of HDL particles of smaller size (Pϭ3.4ϫ10 Ϫ17 ) in a fourth study (nϭ3375). In a combination of 5 cardiovascular disease case-control studies (nϭ4658 cases and 11 459 controls), a higher gene score was associated with a lower cardiovascular disease risk (per-allele odds ratio, 0.94; 95% confidence interval, 0.90 to 0.98; Pϭ1.2ϫ10 Ϫ3 ; odds ratio for highest versus lowest gene score, 0.69; 95% confidence interval, 0.55 to 0.86; Pϭ1.0ϫ10 Ϫ3 ). Conclusions-A gene score based on 2 PLTP single nucleotide polymorphisms is associated with lower PLTP transcription and activity, an increased number of HDL particles, smaller HDL size, and decreased risk of cardiovascular disease. These findings indicate that PLTP is a proatherogenic entity and suggest that modulation of specific elements of HDL metabolism may offer cardiovascular benefit. (Circulation. 2010;122:470-477.)
gene with a profound impact on HDL metabolism is phospholipid transfer protein (PLTP). In plasma, PLTP resides on high-density lipoprotein (HDL) and is involved in HDL remodeling by facilitating the fusion of medium-sized HDL 3 particles; this process results in the formation of larger HDL 2 and smaller pre-␤ HDL particles. [5] [6] [7] PLTP also mediates the shedding of phospholipid-rich surface fragments from triglyceride-rich lipoproteins during lipoprotein lipase-mediated lipolysis, which are important precursors of HDL particles. 8 In humans, plasma PLTP activity has been found to be slightly increased in diabetes mellitus, obesity, and the metabolic syndrome. 9 Additionally, several studies suggest that a higher PLTP activity is associated with an increased risk of atherosclerosis, 10 -12 but another study suggests the opposite. 13 Initially, 2 small studies revealed an association between common genetic PLTP variants and HDL cholesterol levels 14 and obesity-linked parameters. 15 However, a paucity of data exists in humans on the consequences of common variants in the PLTP gene for PLTP activity and CVD risk. We therefore set out to test the hypothesis that a lower PLTP activity, as determined by genetic predisposition, is associated with parameters related to HDL remodeling and with the risk of CVD.
To select common genetic variants predictive of PLTP activity, we first genotyped PLTP tagging single nucleotide polymorphisms (SNPs) in 2 Dutch studies for which data on plasma PLTP activity were available at baseline. Second, we constructed a gene score composed of the genetic variants predictive of lower PLTP activity in both studies and evaluated its association with human hepatic PLTP RNA expression in another study. Third, we determined whether this PLTP gene score was associated with parameters related to HDL remodeling in a prospective case-control study nested in the European Prospective Investigation of Cancer (EPIC)-Norfolk cohort study. Fourth, we assessed whether this gene score was associated with decreased CVD risk in the EPIC-Norfolk case-control study and 4 other CVD case-control studies, with a total number of 4658 cases and 11 459 controls.
Methods
Studies were approved by Institutional Review boards and conducted according to the Declaration of Helsinki. Written informed consent was obtained from all participants.
Data Sources

Diabetes Atorvastatin Lipid Intervention (DALI) Study
The Diabetes Atorvastatin Lipid Intervention (DALI) double-blind, randomized, placebo-controlled multicenter study evaluated the effect of atorvastatin 10 versus 80 mg on lipid metabolism, endothelial function, coagulation, and inflammatory factors in 215 unrelated Dutch men and women with type 2 diabetes mellitus. 16
Groningen Case-Control Study
This study enrolled type 2 diabetic patients (nϭ87) and age-matched nondiabetic control subjects (nϭ82) to determine the extent to which intima-media thickness is related to plasma PLTP activity in subjects with and without diabetes mellitus. 17
(Expanded) Human Liver Cohort (HLC)
The Human Liver Cohort (HLC) was assembled from a total of 957 liver samples acquired from 2 separate studies. The first study (HLC1) involved white individuals from 3 independent liver collections at tissue resource centers at Vanderbilt University, the University of Pittsburgh, and Merck Research Laboratories. The second study (HLC2) involved white individuals undergoing Roux-en-Y gastric bypass surgery at Massachusetts General Hospital. 18 
EPIC-Norfolk Prospective Case-Control Study
The design and characteristics of the EPIC-Norfolk prospective population study have been described extensively. 19 Briefly, 25 663 healthy men and women between 45 and 79 years of age were recruited from age-sex registers of general practices in Norfolk, UK. We designed a prospective case-control study nested within this cohort. Case ascertainment has been described previously. 20 Cases were those having fatal or nonfatal coronary artery disease (CAD) during follow-up. Controls were study participants who remained free of CVD during follow-up. This nested case-control set contained 1138 cases and 2237 matched controls.
Cambridge Heart Antioxidant Study (CHAOS)-Studies of Epidemiology and Risk Factors in Cancer Heredity (SEARCH) CAD Case-Control Study
Cases were white European participants from the Cambridge Heart Antioxidant Study (CHAOS). 21 Controls were recruited from agesex registers of general practices from around the East Anglian region. 22 For this analysis, the CHAOS-Studies of Epidemiology and Risk Factors in Cancer Heredity (SEARCH) case-control study comprised 638 cases and 1814 controls.
Premature Atherosclerosis Patients and Sanquin Blood Bank Controls
We selected consecutive Dutch premature atherosclerosis patients (nϭ935: mean age, 43.9Ϯ5.4 years; 708 men: mean age, 43.1Ϯ5.4 years; and 227 women: mean age, 42.4Ϯ5.6 years) who qualified for inclusion after a myocardial infarction, surgical or percutaneous coronary revascularization, a coronary angiogram with evidence of at least 70% stenosis in a major epicardial artery, vascular claudication with an abnormal peripheral artery angiography, or a surgical or percutaneous peripheral arterial revascularization before 51 years of age. Patients were recruited at the Atherosclerosis Outpatient Clinic of the Academic Medical Center, Amsterdam, the Netherlands. Controls (nϭ1440) were recruited at their blood donation session at one of the collection sites of the Sanquin Blood Bank covering the northwest section the Netherlands, which geographically overlaps the Amsterdam patient cohort.
The Rotterdam Study
The Rotterdam Study is a prospective population-based cohort study to investigate the determinants of chronic diseases among participants Ն55 years of age. 23 The current analysis includes 5195 participants who were free of CHD (defined as coronary heart mortality, myocardial infarction, or coronary revascularization) at baseline and had genotype data available. Over a median follow-up of 11.89 years, 674 individuals developed CHD, and 4521 subjects remained free of CHD at the end of the follow-up.
Stockholm Heart Epidemiology Programme Case-Control Study
The Stockholm Heart Epidemiology Programme (SHEEP) study is a population-based case-control study of nonfatal first-event acute myocardial infarction in white Swedish men and women from Stockholm County, Sweden, who were 45 to 70 years of age. Details of the study design have been published previously. 24 For this analysis, the SHEEP case-control study comprised 1117 cases and 1447 controls.
Laboratory Analyses
Genotyping
Tagging SNPs for PLTP were selected with the HAPMAP database 25 and the TAGGER algorithm using a pairwise tagging approach. 26 Briefly, we selected from HAPMAP all common genetic variants (minor allele frequency Ͼ0.1) in the PLTP locus in a population of European ancestry. A tagging SNP approach uses the knowledge of associations between genetic variants (linkage disequilibrium [LD] structure) to limit the number of SNPs that needs to be genotyped. TagSNPs are those SNPs that most effectively represent (or "tag") all the SNPs in a particular locus. We selected tagSNPs using an r 2 cutoff level Ͼ0.8.
Biochemical Analyses
PLTP activity was measured with a liposome vesicles-HDL system in both the DALI and Groningen studies, whereas PLTP concentration was analyzed only in the DALI study. 27 Plasma PLTP activity is expressed relative to control pool plasma. We measured HDL size by 4% to 30% nondenaturing polyacrylamide gradient gel electrophoresis as previously described. 28 HDL particle number and HDL size were measured with an automated nuclear magnetic resonance spectroscopic assay as described. 29 See the online-only Data Supplement for additional information on data sources and laboratory analyses.
Statistical Analyses
All statistical analyses were performed with SPSS version 16.0.2. Two-sided P values of Ͻ0.05 were considered statistically significant. Effects of single SNPs or of PLTP gene score on continuous variables were examined by ANOVA; in case of significant differences, per-allele effects and corresponding 95% confidence intervals (CIs) were estimated with linear regression analysis. To estimate the relative risk of CVD in EPIC-Norfolk, conditional logistic regression was used to calculate odds ratios (ORs) and 95% CIs per allele change in PLTP gene score, with the lowest PLTP gene score as the reference category. Conditional logistic regression took into account the matching for sex, age, and enrollment time and was adjusted for Framingham Risk Score. 30 In the Premature Atherosclerosis Patients and Sanquin Blood Bank Controls (PAS/SQ), CHAOS-SEARCH, Rotterdam, and SHEEP studies, differences between cases and controls were analyzed by standard contingency table analysis with 2-tailed 2 test probabilities; linearity of this relationship was assessed with logistic regression analysis. To estimate the relative risk of CVD in all studies combined, logistic regression was used. Heterogeneity of the relationship between PLTP gene score and CVD risk across different studies was assessed by the use of a linear mixed model with study random effects for the estimated study-specific log OR. LD plots were created with Haploview, version 4.1. 31
Results
To select common genetic variants predictive of PLTP activity, we Individuals with data on the indicated SNP genotype and on PLTP activity were included. Values are given as mean (SD). PLTP activity is presented as a percentage of pool plasma. Individuals with data on the indicated SNP genotype and on PLTP activity were included. Values are given as mean (SD). PLTP activity is presented as a percentage of pool plasma.
(presence of 0, 1, or 2 T alleles) on the basis of their effects on PLTP activity in these 2 studies (177 participants in DALI and 145 in the Groningen Study had complete gene score data). This gene score represents the number of PLTP activity-decreasing alleles, ranging from 0 to 4. A higher PLTP gene score was associated with lower PLTP concentration (Ϫ0.69 mg/L [95% CI, Ϫ0.24 to Ϫ1.14] per allele; Pϭ3.0ϫ10Ϫ 3 ) and activity (Ϫ6.0 AU [95% CI, Ϫ3.4 to Ϫ8.6] per allele; Pϭ1.2ϫ10 Ϫ5 ) in the DALI study and lower PLTP activity (Ϫ3.9 AU [95% CI, Ϫ2.1 to Ϫ5.7] per allele; Pϭ3.5ϫ10 Ϫ5 ) in the Groningen study ( Figure 1A through 1C). In the 2 studies combined, the per-allele effect of PLTP gene score on PLTP activity was Ϫ5.0 AU (95% CI, Ϫ3.4 to Ϫ6.7; Pϭ4.4ϫ10 Ϫ9 ). To exclude an important contribution of type 2 diabetes, we reassessed the relationship, selecting only the Groningen study participants without diabetes mellitus, and found similar associations between PLTP gene score and PLTP activity (Ϫ4.7 AU [95% CI, Ϫ2.4 to Ϫ7.1] per allele; Pϭ1.3ϫ10 Ϫ4 ). In addition, in pooled data from both studies, PLTP gene score was significantly associated with PLTP activity after controlling for age, sex, and diabetes status (Ϫ5.1 AU [95% CI, Ϫ3.5 to Ϫ6.7] per allele; Pϭ4.1ϫ10 Ϫ9 ). Finally, to validate the PLTP gene score, we evaluated its association with PLTP RNA expression in the expanded HLC and found that it was linearly associated with less efficient PLTP transcription (Ϫ0.47 AU per allele [95% CI, Ϫ0.058 to Ϫ0.037]; Pϭ3.2ϫ10 Ϫ18 ; Figure 1D ).
PLTP Gene Score and HDL Remodeling Parameters
Characteristics of study participants across PLTP gene score categories in EPIC-Norfolk are shown in Table I in the online-only Data Supplement. Conventional risk factors did not differ between PLTP gene score categories. Standard lipid profiles were similar between gene scores, although HDL cholesterol levels showed a nonsignificant tendency to be lower with higher gene scores. There were no differences in apolipoprotein A-I (a structural component of HDL) or apolipoprotein B (a structural component of very-low-density lipoprotein) levels.
We determined whether the PLTP gene score was associated with parameters related to HDL remodeling. The number of HDL particles increased with a rising PLTP gene score (0.37 nmol/L [95% CI, 0.16 to 0.57] per allele; Pϭ6.2ϫ10 Ϫ4 ; Figure 2A ). This was due predominantly to a higher concentration of small HDL particles (0.79 nmol/L [95% CI, 0.61 to 0.97] per allele; Pϭ3.4ϫ10 Ϫ17 ; Figure 2b ), whereas the number of large HDL particles actually decreased with higher PLTP gene scores (Ϫ0.37 nmol/L [95% CI, Ϫ0.50 to Ϫ0.24] per allele; Pϭ3.9ϫ10 Ϫ8 ; Figure 2C ). Consequently, people with a higher PLTP gene score exhibited a lower HDL size as measured by nuclear magnetic resonance spectroscopy (Ϫ50 pm [95% CI, Ϫ32 to Ϫ67] per allele; Pϭ2.8ϫ10 Ϫ8 ; Figure  2D ). HDL size measured by gradient gel electrophoresis yielded a similar result (Ϫ47 pm [95% CI, Ϫ31 to Ϫ63] per allele; Pϭ9.0ϫ10 Ϫ9 ).
PLTP Gene Score and Risk of CVD
Next, we determined whether PLTP gene score was associated with an altered risk of CVD. Combining data from all 5 CVD studies, we found an inverse association between PLTP gene score and risk of CVD (OR, 0.94 per allele increase in score; 95% CI, 0.90 to 0.98; Pϭ1.2ϫ10 Ϫ3 ; Figure 3 ). This association is consistent with the proposed biological role of PLTP. Although the pattern of association between gene score and risk of CVD appears to differ between studies, we found no formal statistical evidence of heterogeneity between studies (Pϭ0.16). However, in light of evidence for heterogeneity in genetic structure between Swedish and other European populations, [32] [33] [34] [35] we also present combined analyses after exclusion of the SHEEP study. In only British and Dutch individuals, the association between PLTP gene score and CVD risk was more pronounced (OR, 0.91 per allele; 95% CI, 0.87 to 0.95; Pϭ2.3ϫ10 Ϫ5 ; Figure 3 ). Comparing groups with the highest exposure differential, reflecting the greatest difference in PLTP activity, we found that, in all studies combined, the OR for CVD for the highest versus the lowest gene score was 0.69 (95% CI, 0.55 to 0.86; Pϭ1.0ϫ10 Ϫ3 ; Table 3 ). In only British and Dutch individuals, the OR for CVD for the highest versus the lowest gene score was 0.58 (95% CI, 0.45 to 0.75; Pϭ3.2ϫ10 Ϫ5 ).
Discussion
In the present study we composed a gene score from 2 PLTP tagSNPs that were associated with plasma PLTP activity and PLTP concentration. This gene score was associated with lower PLTP activity, less efficient PLTP transcription, an increased number of HDL particles, smaller HDL size, and lower risk of CVD.
Common Genetic Variants in PLTP and PLTP Activity
An understanding of correlations among nearby gene variants (LD structure) permits the selection of tagSNPs (ie, SNPs that most efficiently represent other SNPs that are not genotyped) in a genomic region with high LD. 26 We found that alleles of 2 PLTP tagSNPs were linearly associated with lower plasma PLTP activity in 2 independent studies and with PLTP transcription efficiency in a third study. Although it remains unknown which genetic variant is causally responsible for these associations, these data provide solid support for the hypothesis that the PTLP gene score is a valid genetic proxy for PLTP activity.
PLTP Activity and In Vivo HDL Remodeling Parameters
In vitro, PLTP remodels HDL into large and small particles and mediates the dissociation of lipid-poor apolipoprotein A-I. 6,36 -39 Evidence indicates that the actions of PLTP initially lead to the formation of a fusion product of 2 HDL particles, which subsequently rearranges into 3 small conversion products or alternatively into 1 large conversion product in a process that is accompanied by the shedding of apolipoprotein A-I. 5 Our findings suggest that the net effect of these actions in vivo is a reduction in the number of small HDL particles and an increase in the number of large HDL particles. This is in line with observations in patients with type 1 diabetes mellitus in whom elevated PLTP activity was associated with more large and fewer small HDL particles. 40 In combination with the absence of a difference in apolipoprotein A-I and HDL cholesterol levels, this suggests that, in humans, across this range of PLTP activity modulation, PLTP does not materially affect apolipoprotein production or catabolism but repackages HDL cholesterol into fewer and larger particles in vivo. This contrasts with an article by Engler et al, 14 which revealed a small association signal for a PLTP SNP with HDL cholesterol levels in 107 hyperalphalipoproteinemic patients. Unfortunately, in this study, plasma PLTP activity was not analyzed.
PLTP Activity and CVD Risk
In mice, systemic expression of PLTP has been shown to be proatherogenic using PLTP knockout 41 and human 42, 43 and murine 44 PLTP overexpression models. Most studies in humans accordingly show a positive association between plasma PLTP activity and atherosclerosis. 9 Schlitt et al 12 reported that PLTP activity is elevated in CAD patients compared with healthy control subjects. In another study, PLTP activity was independently and positively related to carotid intima-media thickness, a measure of subclinical atherosclerosis, in patients with type 2 diabetes mellitus. 10 Associations between PLTP gene score and HDL remodeling parameters in EPIC-Norfolk. There is a positive association between PLTP gene score and HDL particle number (A), a positive association between PLTP gene score and small HDL (B), and a negative association between the gene score and large HDL (C). With increasing PLTP gene score, the average HDL size is smaller (D). Error bars represent 95% CIs; P values are for linearity.
Furthermore, it has been reported that high plasma PLTP activity was related to fatal and nonfatal cardiovascular events in CAD patients treated with statins. 11 Only 1 study has demonstrated a lower plasma PLTP activity in subjects with peripheral vascular disease. 13 To date, no studies have examined the relationship between genetic variants in PLTP and the risk of CVD.
We found consistent relationships between PLTP gene score and CVD risk in 4 of the 5 studies. There are several potential explanations for the absence of association in the SHEEP study. It may be the result of sampling variation or of differences in LD structure between study populations, reflecting the fact that we are not directly assessing the causal variant(s) underlying these associations. [32] [33] [34] [35] However, genotype frequencies for the 2 SNPs and for the gene score were similar between all studies (Tables II and III in the onlineonly Data Supplement) . Alternatively, other genetic and environmental factors may specifically affect the relation between PLTP activity and CVD risk in the Swedish population. These considerations notwithstanding, our findings using the combined data of all 5 CVD studies comprising Ͼ16 000 individuals indicate that a genetic predisposition toward lower PLTP activity is associated with a lower risk of CVD. The relationship between gene score and CVD risk was linear, suggesting a "gene-dose" effect. Furthermore, in all studies combined, people with the highest PLTP gene score exhibited a 31% reduction in CVD risk compared with the lowest PLTP gene score.
Under the assumptions of mendelian randomization, 45 genetic association analyses are expected to be less confounded than direct assessments of plasma parameters and disease risk. Because variants in the PLTP locus show a very good level of specificity to PLTP transcription, plasma PLTP concentration and activity, and HDL particle number and size, we believe the association between these genetic variants and CVD risk allows us to make more robust statements about the relationship between this biological risk marker and disease susceptibility. Taken together, our results strengthen the hypothesis that PLTP has proatherogenic potential.
Potential Biological Mechanism
The PLTP gene score was not associated with any conventional risk factor for CVD but was strongly associated with HDL particle distribution. It is therefore tempting to speculate that the increased numbers of (small) HDL particles explain the lower CVD risk in people with a high PLTP gene score. Theoretically, such an increase may augment plasma capacity to accept cholesterol from cellular cholesterol efflux pathways, the most important putative antiatherogenic property of HDL. 46 This would be in line with observations in mice that elevation of systemic PLTP was found to impair excretion of macrophage cholesterol into the feces. 47 We attempted to further substantiate this possibility with our own data but found that statistical adjustment for HDL particle parameters in EPIC-Norfolk did not materially affect the relationship between PLTP gene score and CAD risk (data not shown). However, even if an HDL particle parameter would be the mediator of the observed risk reduction, random measurement error in this variable can be expected to limit its ability to abolish the relationship between PLTP gene score and CVD risk in a statistical model; therefore, this potential mechanism cannot be excluded.
In recent years, the focus of HDL research has gradually shifted from HDL cholesterol levels to HDL functionality, reflecting the fact that HDL cholesterol levels may be a poor measure of the efficiency of these particles to perform their antiatherogenic functions in vivo. 46 Our finding of a reproducible association between cardiovascular risk and genetic variants with a clear impact on HDL particle distribution, but not on HDL cholesterol levels, is in general agreement with this concept.
Conclusions
We demonstrate for the first time in humans that genetic variation at the PLTP locus is associated with reduced PLTP messenger RNA transcription efficiency, a lower plasma PLTP activity, a higher concentration of HDL particles of smaller size, and a reduced risk of CVD, suggesting that PLTP has proatherogenic potential. Our findings are consistent with the notion that modulation of specific elements of HDL metabolism may offer cardiovascular benefit. 
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